ArticleArthritis care & research2026
Prevalence of Systemic Lupus Erythematosus in Australia, 2010-2022: A Population-Based Study Using Linked National Administrative Health Data.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveSystemic lupus erythematosus (SLE) is a heterogenous inflammatory condition with widely varying global prevalence estimates. The frequency of SLE in the general population of Australia has been reported to be notably lower than contemporary estimates in countries such as the United States or United Kingdom, at 19 to 39 per 100,000 as opposed to 65 to 97 per 100,000. This study aimed to develop a national SLE cohort using linked administrative data sets and to estimate prevalence using this approach.
methodsWe developed an algorithm to identify SLE cases using the National Health Data Hub, a linked national administrative data asset, which includes data on medications dispensed and medical services subsidized under Australia's universal subsidized coverage schemes, hospital admissions, and deaths. These classification criteria were developed with an expert panel of rheumatologists. Individuals were classified as "certain," "uncertain," or "no SLE." Cohort characteristics were described, and period prevalence (2010-2022) was calculated.
resultsA cohort of 26,788 individuals with SLE were identified, which comprised 16,294 certain cases and 10,494 uncertain cases. The period prevalence of SLE in Australia from 2010 to 2022 was 77 to 127 per 100,000 (certain cases or overall cases). Among the certain cases, just over half had received care for SLE only in an outpatient setting.
conclusionThis is the first Australian SLE study using comprehensive linked administrative health data, and it identified higher prevalence than previously reported, more closely aligning with international estimates. This algorithm may serve as a foundation for future Australian and international studies seeking to identify SLE in administrative health data sets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.